The majority of inflammatory bowel disease (IBD) patients can live normal productive lives;
but long-term ulcerative colitis is associated with a higher risk of dysplasia and colorectal cancer.
Anti-TNF drugs remain the first-line therapy for moderate-to-severe IBD patients but these
drugs have several drawbacks for the majority of patients. This study assessed one-year followup
of ulcerative colitis patients receiving biological therapy. Selected twenty-eight patients with
moderate to severe ulcerative colitis treated with biological therapy for at least one year were enrolled.
Clinical and laboratory assessments were performed for patients before and after the biological
treatment as well as assessments of clinical response and remission.
The results showed that after one year, patients (75%) clinical responded and clinical
remission was in 46.4% of them. There was a significant improvement in Mayo Score
and Mayo Endoscopic Sub-score.